DOCSLIB.ORG

Alimentary Tract and Metabolism Drug Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alimentary Tract and Metabolism Drug Poster Alimentary Tract and Metabolism Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson Magnesium Sulfate Magnesium Sulfate Calcium Chloride Papaverine Potassium Chloride Guanadine Streptomycin Azulfidine Banthine Sus-phrine Sulfite Fungizone Cortef Acetate Achromycin Pamine Pro-Banthine Cortef Acetate Meticorten Medicortelone Aristocort Decadron ( Magnesium Sulfate ) ( Magnesium Sulfate ) ( Calcium Chloride ) ( Papaverine ) ( Potassium Chloride ) ( Guanidine ) ( Streptomycin ) ( Sulfasalazine ) ( Methantheline ) ( Epinephrine ) ( Amphotericin B ) ( Hydrocortisone ) ( Tetracycline ) ( Methylscopolamine ) ( Propantheline ) ( Hydrocortisone ) ( Prednisone ) ( Prednisolone ) ( Triamcinolone ) ( Dexamethasone ) LAXATIVE MINERAL SUPPLEMENT MINERAL SUPPLEMENT GASTROINTESTINAL DISORDERS MINERAL SUPPLEMENT ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. GASTROINTESTINAL DISORDERS STOMATOLOGICAL PREP ANTIDIAR., ANTIINFLA. & ANTIINF. STOMATOLOGICAL PREP STOMATOLOGICAL PREP GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. STOMATOLOGICAL PREP STOMATOLOGICAL PREP Approved 1900s Approved 1900s Approved 1900s Approved 1915 Approved 1920s Approved 1939 Approved 1946 Approved 1950 Approved 1950s Approved 1951 Approved 1951 Approved 1953 Approved 1953 Approved 1953 Approved 1953 Approved 1953 Approved 1955 Approved 1955 Approved 1957 Approved 1958 Diabinese Tenuate Ionamin Durabolin Diphenoxylate Lomotil Antrenyl Polymyxin B Phenformin Celestone Orinase Flagyl Neo-Fradin Osmitrol Vancocin Mycostatin Neo-Fradin Dymelor Anavar 8-Hour Bayer ( Chlorpropamide ) ( Diethylpropion ) ( Phentermine ) ( Nandrolone ) ( Diphenoxylate ) ( Atropine & Diphenoxylate ) ( Oxyphenonium ) ( Polymyxin B ) ( Phenformin ) ( Betamethasone ) ( Tolbutamide ) ( Metronidazole ) ( Neomycin ) ( Mannitol ) ( Vancomycin ) ( Nystatin ) ( Neomycin ) ( Acetohexamide ) ( Oxandrolone ) ( Aspirin ) ANTIDIABETIC AGENT ANTI-OBESITY AGENT ANTI-OBESITY AGENT ANABOLIC AGENT ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIABETIC AGENT ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIABETIC AGENT STOMATOLOGICAL PREP STOMATOLOGICAL PREP LAXATIVE ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIABETIC AGENT ANABOLIC AGENT STOMATOLOGICAL PREP Approved 1958 Approved 1959 Approved 1959 Approved 1959 Approved 1960 Approved 1960 Approved 1960s Approved 1960s Approved 1960s Approved 1961 Approved 1961 Approved 1963 Approved 1964 Approved 1964 Approved 1964 Approved 1964 Approved 1964 Approved 1964 Approved 1964 Approved 1965 Fungizone Tolinase Vibramycin Daricon Anaspaz Pathilon Prantal Gliclazide Minocin Atropen Kantrax Sanorex Lotrimin Hibiclens Vanceril Imodium Cephulac Tagamet Ranitidine Natacyn ( Amphotericin B ) ( Tolazamide ) ( Doxycycline ) ( Oxyphencyclimine ) ( Hyoscyamine ) ( Tridihexethyl ) ( Diphemanil ) ( Gliclazide ) ( Minocycline ) ( Atropine ) ( Kanamycin ) ( Mazindol ) ( Clotrimazole ) ( Chlorhexidine ) ( Beclomethasone ) ( Loperamide ) ( Lactulose ) ( Cimetidine ) ( Ranitidine ) ( Natamycin ) STOMATOLOGICAL PREP ANTIDIABETIC AGENT STOMATOLOGICAL PREP GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS ANTIDIABETIC AGENT STOMATOLOGICAL PREP GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTI-OBESITY AGENT STOMATOLOGICAL PREP STOMATOLOGICAL PREP ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. LAXATIVE ACID RELATED DISORDERS ACID RELATED DISORDERS STOMATOLOGICAL PREP Approved 1966 Approved 1966 Approved 1967 Approved 1970s Approved 1970s Approved 1970s Approved 1970s Approved 1970s (AUS/IND/PHL) Approved 1971 Approved 1973 Approved 1973 Approved 1973 Approved 1975 Approved 1976 Approved 1976 Approved 1976 Approved 1976 Approved 1977 Approved 1977 Approved 1978 Natacyn Reglan Transderm Pirenzepine Domperidone Magnacort Carafate Glucotrol Cesamet Marinol Pepcid L-Carnitine Ammonul Axid Cytotec Prilosec PhosLo Fenfluramine Redux Zofran ( Natamycin ) ( Metoclopramide ) ( Scopolamine ) ( Pirenzepine ) ( Domperidone ) ( Hydrocortamate ) ( Sucralfate ) ( Glipizide ) ( Nabilone ) ( Marinol ) ( Famotidine ) ( L-Carnitine ) ( Benzoic & Phenylacetic Acids ) ( Nizatidine ) ( Misoprostol ) ( Omeprazole ) ( Calcium Acetate ) ( Fenfluramine ) ( Dexfenfluramine ) ( Ondansetron ) ANTIDIAR., ANTIINFLA. & ANTIINF. GASTROINTESTINAL DISORDERS ANTIEMETIC & ANTINAUSEANT ACID RELATED DISORDERS GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ACID RELATED DISORDERS ANTIDIABETIC AGENT ANTIEMETIC & ANTINAUSEANT ANTIEMETIC & ANTINAUSEANT ACID RELATED DISORDERS OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD ACID RELATED DISORDERS ACID RELATED DISORDERS ACID RELATED DISORDERS MINERAL SUPPLEMENT ANTI-OBESITY AGENT ANTI-OBESITY AGENT ANTIEMETIC & ANTINAUSEANT Approved 1978 Approved 1979 Approved 1979 Approved 1980s (EUR/JPN) Approved 1980s (EUR/CAN) Approved 1980s Approved 1981 Approved 1984 Approved 1985 Approved 1985 Approved 1986 Approved 1986 Approved 1987 Approved 1988 Approved 1988 Approved 1989 Approved 1990 Approved 1990s Approved 1990s Approved 1991 Orfadin Propulsid Kytril Cystagon Prevacid Amaryl Precose Glucophage Aphthasol Glyset Anzemet Pulmicort Meridia Prelay Prandin Prevpac Arthrotec Zemplar Isopto Homatropine AcipHex ( Nitisinone ) ( Cisapride ) ( Granisetron ) ( Cysteamine ) ( Lansoprazole ) ( Glimepiride ) ( Acarbose ) ( Metformin ) ( Amlexanox ) ( Miglitol ) ( Dolasetron ) ( Budesonide ) ( Sibutramine ) ( Troglitazone ) ( Repaglinide ) ( Amoxicillin, Clarithromycin & Lansoprazole ) ( Diclofenac & Misoprostol ) ( Paricalcitol ) ( Homatropine ) ( Rabeprazole ) OTHER ALIM. TRACT & MET. PROD GASTROINTESTINAL DISORDERS ANTIEMETIC & ANTINAUSEANT OTHER ALIM. TRACT & MET. PROD ACID RELATED DISORDERS ANTIDIABETIC AGENT ANTIDIABETIC AGENT ANTIDIABETIC AGENT STOMATOLOGICAL PREP ANTIDIABETIC AGENT ANTIEMETIC & ANTINAUSEANT ANTIDIAR., ANTIINFLA. & ANTIINF. ANTI-OBESITY AGENT ANTIDIABETIC AGENT ANTIDIABETIC AGENT ACID RELATED DISORDERS ACID RELATED DISORDERS VITAMIN ACID RELATED DISORDERS ACID RELATED DISORDERS Approved 1991 Approved 1993 Approved 1993 Approved 1994 Approved 1995 Approved 1995 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1999 Approved 1999 Xenical Avandia Actos Protonix Lotronex Colazal Starlix Glucovance NexIUM Canasa Rebetol Zelnorm Alinia Eloxatin Gleevec Hepsera Pegasys SecreFlo Pediarix Avandamet ( Orlistat ) ( Rosiglitazone ) ( Pioglitazone ) ( Pantoprazole ) ( Alosetron ) ( Balsalazide ) ( Nateglinide ) ( Glyburide & Metformin ) ( Esomeprazole ) ( Mesalamine ) ( Ribavirin ) ( Tegaserod ) ( Nitazoxanide ) ( Oxaliplatin, 5-Fluorouracil, & Leucovorin ) ( Imatinib ) ( Adefovir Dipivoxil ) ( Peginterferon Alfa-2a ) ( Secretin ) ( Pediarix ) ( Metformin & Rosiglitazone ) ANTI-OBESITY AGENT ANTIDIABETIC AGENT ANTIDIABETIC AGENT ACID RELATED DISORDERS GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIABETIC AGENT ANTIDIABETIC AGENT ACID RELATED DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD ANTIDIAR., ANTIINFLA. & ANTIINF. OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD ANTIDIABETIC AGENT Approved 1999 Approved 1999 Approved 1999 Approved 2000 Approved 2000 Approved 2000 Approved 2000 Approved 2000 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Approved 2002 Metaglip Emend Zavesca Aloxi Oxytrol Prevacid Naprapac Xifaxan Avastin Erbitux Zegerid Tygacil Baraclude Nexavar Actoplus MET Avandaryl Amitiza Tyzeka Duetact Torisel Janumet ( Glipizide & Metformin ) ( Aprepitant ) ( Miglustat ) ( Palonosetron ) ( Oxybutynin ) ( Lansoprazole & Naproxen ) ( Rifaximin ) ( Bevacizumab ) ( Cetuximab ) ( Omeprazole & Sodium Bicarbonate ) ( Tigecycline ) ( Entecavir ) ( Sorafenib ) ( Metformin & Pioglitazone ) ( Glimepiride & Rosiglitazone ) ( Lubiprostone ) ( Telbivudine ) ( Glimepiride & Pioglitazone ) ( Temsirolimus ) ( Metformin & Sitagliptin ) ANTIDIABETIC AGENT ANTIEMETIC & ANTINAUSEANT OTHER ALIM. TRACT & MET. PROD ANTIEMETIC & ANTINAUSEANT OTHER ALIM. TRACT & MET. PROD ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. OTHER ALIM. TRACT & MET. PROD OTHER ALIM. TRACT & MET. PROD ANTIDIABETIC AGENT ANTIDIABETIC AGENT GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS ANTIDIABETIC AGENT GASTROINTESTINAL DISORDERS ANTIDIABETIC AGENT Approved 2002 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2004 Approved 2004 Approved 2004 Approved 2004 Approved 2005 Approved 2005 Approved 2005 Approved 2005 Approved 2005 Approved 2006 Approved 2006 Approved 2006 Approved 2007 Approved 2007 Rotari Cimzia Enterig Tysabri Viread Prandimet Zenpep Afinitor Votrient Oravig Oravig Herceptin Pancreaze Vimovo Cayston
Load more

Recommended publications
  • United States Patent Office
    3,092,548 United States Patent Office Patented June 4, 1963 2 are the various side effects that occur in an appreciable 3,092,548 number of patients, the foremost of which are a blurring METHOD OF TREATING PEPTICULCERS WITH PANTOTHENECACD of vision, drowsiness and a general dry condition mani Albert G. Worton, Columbus, Ohio, assignor to The fested by a retarded salivation, reduction of perspiration Warren-Teed Products Company, Columbus, Ohio, a 5 and diminished urinary output. Other side effects which corporation of Ohio occur in some cases are glaucoma, stimulation of the cen No Drawing. Filed Oct. 27, 1960, Ser. No. 65,256 trol nervous system and in severe cases cardiac and respi 5 Claims. (Ci. 67-55) ratory collapse. These side effects increase to Some de gree with the increase in dosage. Despite the side effects This invention relates to preparation adapted for use O these compounds are fairly selective and highly effective in treating disorders of the gastro-intestinal tract, more in decreasing the volume and acidity of gastric secretion particularly in treating peptic ulcer, both of the duodenal and in reducing gastrointestinal motility. and gastric type, for hyperacidity, hypertropic gastritis, Understandably, the main problem in the past has been splenic flexure syndrome, biliary dyskinesia (postchole to provide a dosage of anticholinergic drug which will cystectomy syndrome) and hiatal hernia or other condi achieve the most beneficial results possible and yet mini tions where anticholinergic effect, either spasmolytic or mize the undesired side effects. One of the objects of antisecretory is indicated or where antiuicerogenic effect this invention is to provide novel compositions containing is indicated.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • United States Patent (19) 11 4,111,203 Theeuwes (45) "Sep
    United States Patent (19) 11 4,111,203 Theeuwes (45) "Sep. 5, 1978 54) OSMOTIC SYSTEM WITH MEANS FOR Primary Examiner-Benjamin R. Padgett MPROVING DELVERY KNETCS OF Assistant Examiner-T. S. Gron SYSTEM Attorney, Agent, or Firm-Paul L. Sabatine; Thomas E. 75 Inventor: Felix Theeuwes, Los Altos, Calif. Ciotti; Edward L. Mandell 73) Assignee: Alza Corporation, Palo Alto, Calif. 57 ABSTRACT * Notice: The portion of the term of this patent An osmotic system for delivering a beneficial agent is subsequent to Sep. 5, 1995, has been disclosed. The system comprises a wall surrounding a disclaimed. compartment and has a passageway through the wall for delivering agent from the compartment. The wall is (21) Appl. No.: 744,089 formed of a material permeable to the passage of an (22 Filed: Nov. 22, 1976 external fluid and impermeable to the passage of agent. 51) Int. Cl’............................................. A61M31/00 The compartment contains an agent that is soluble in 52 U.S. C. ..................................... 128/260; 206/0.5; the fluid and exhibits an osmotic pressure gradient 222/130; 222/193; 222/389; 222/395; 222/491; across the wall against the fluid, or the compartment 424/19 contains an agent that has limited solubility in the fluid 58) Field of Search ............... 128/260, 261,268, 272; and exhibits a limited osmotic pressure gradient across 424/15, 19-22, 33, 37; 222/491,395, 193,389, the wall against the fluid. The compartment also con 130; 206/0.5 tains means for increasing the amount of agent deliv ered from the system. The means comprises a film sur (56) References Cited rounding an osmagent with the film formed of a mate U.S.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]